+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

S

Actively Recruiting

Geographic Atrophy GA is an advanced form of age-related macular degeneration AMD that causes loss of light-sensitive cells in the retina, leading to severe vision loss when the central area fovea is affected. This trial investigates whether GAL-101, given as eye drops, can slow the growth of GA and prevent it from reaching the fovea in patients with non-foveal GA secondary to non-neovascular AMD. Participants will be randomly assigned to receive either GAL-101 eye drops or placebo drops without the active drug. During clinic visits, patients will apply three doses of one drop each at 5-minute intervals under supervision. Outside visits, patients will self-administer two doses daily at 5-minute intervals. The treatment period lasts from 12 to 24 months depending on randomization, with scheduled visits for safety and efficacy assessments at baseline, 2 weeks by phone, and at 1, 3, 6, 9, and 12 months, then every 3 months until the last patient completes 12 months of treatment. Participants will attend regular clinic visits for imaging and vision tests to assess changes in GA lesion size and photoreceptor degeneration. The study uses imaging and vision charts to monitor eye health and drug effects over time. Safety assessments and adherence checks will be part of these visits. The total participation duration varies but includes at least 12 months of treatment and follow-up until study completion, expected in 2027.

Age: 55Years +All GendersPhase 2
24 locations